(Q51571259)

English

Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.

scientific article published in March 1998

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

1 reference

based on heuristic

inferred from title

author name string

Davoren PM

1

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Kelly W

2

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Gries FA

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Hubinger A

4

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Whately-Smith C

5

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Alberti KG

6

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

publication date

1 March 1998

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

47

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

3

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

250-256

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Regulation of glucose uptake by muscle. 9. Effects of fatty acids and ketone bodies, and of alloxan-diabetes and starvation, on pyruvate metabolism and on lactate-pyruvate and L-glycerol 3-phosphate-dihydroxyacetone phosphate concentration ratios in

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Operation of Randle's cycle in patients with NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effect of fatty acids on glucose production and utilization in man

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

THE EFFECT OF NICOTINIC ACID IN DIABETES MELLITUS

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Inhibition of lipolysis by nicotinic acid and by acipimox

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Glucose, insulin and somatostatin infusion for the determination of insulin sensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Automated enzymatic determination of plasma free fatty acids by centrifugal analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Optimized methods to measure acetoacetate, 3-hydroxybutyrate, glycerol, alanine, pyruvate, lactate and glucose in human blood using a centrifugal analyser with a fluorimetric attachment

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effects of acipimox on serum lipids, lipoproteins and lipolytic enzymes in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Acipimox in the treatment of patients with hyperlipidaemia: a double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effects of acipimox, a nicotinic acid derivative, on lipolysis in human adipose tissue and on cholesterol synthesis in human jejunal mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effect of simvastatin on Lp(a) concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Clinical profile of glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Relationships between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and noninsulin-dependent diabetic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Relationships between plasma-free fatty acid concentration, endogenous glucose production, and fasting hyperglycemia in normal and non-insulin-dependent diabetic individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Acipimox increases glucose disposal in normal man independent of changes in plasma nonesterified fatty acid concentration and whole-body lipid oxidation rate

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Pharmacological profile of a new anti-lipolytic agent: 5-methyl-pyrazine-2-carboxylic acid 4-oxide (acipimox) (1) I - Mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990252-9

7 January 2021

Identifiers

10.1016/S0026-0495(98)90252-9

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 April 2018

http://europepmc.org/abstract/MED/9500558

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51571259&oldid=2232337233"